Last reviewed · How we verify
Evolocumab Drug Substance B
At a glance
| Generic name | Evolocumab Drug Substance B |
|---|---|
| Also known as | AMG 145 |
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose (PHASE1)
- Genetic Testing and Motivational Counseling for FH (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Evolocumab Drug Substance B CI brief — competitive landscape report
- Evolocumab Drug Substance B updates RSS · CI watch RSS
- Amgen portfolio CI